Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Severe acute exacerbations (AE) of idiopathic pulmonary fibrosis (IPF) are medically untreatable and often fatal within days. Recent evidence suggests autoantibodies may be involved in IPF progression. Autoantibody-mediated lung diseases are typically refractory to glucocorticoids and nonspecific medications, but frequently respond to focused autoantibody reduction treatments. We conducted a pilot trial to test the hypothesis that autoantibody-targeted therapies may also benefit AE-IPF patients. METHODS: Eleven (11) critically-ill AE-IPF patients with no evidence of conventional autoimmune diseases were treated with therapeutic plasma exchanges (TPE) and rituximab, supplemented in later cases with intravenous immunoglobulin (IVIG). Plasma anti-epithelial (HEp-2) autoantibodies and matrix metalloproteinase-7 (MMP7) were evaluated by indirect immunofluorescence and ELISA, respectively. Outcomes among the trial subjects were compared to those of 20 historical control AE-IPF patients treated with conventional glucocorticoid therapy prior to this experimental trial. RESULTS: Nine (9) trial subjects (82%) had improvements of pulmonary gas exchange after treatment, compared to one (5%) historical control. Two of the three trial subjects who relapsed after only five TPE responded again with additional TPE. The three latest subjects who responded to an augmented regimen of nine TPE plus rituximab plus IVIG have had sustained responses without relapses after 96-to-237 days. Anti-HEp-2 autoantibodies were present in trial subjects prior to therapy, and were reduced by TPE among those who responded to treatment. Conversely, plasma MMP7 levels were not systematically affected by therapy nor correlated with clinical responses. One-year survival of trial subjects was 46+15% vs. 0% among historical controls. No serious adverse events were attributable to the experimental medications. CONCLUSION: This pilot trial indicates specific treatments that reduce autoantibodies might benefit some severely-ill AE-IPF patients. These findings have potential implications regarding mechanisms of IPF progression, and justify considerations for incremental trials of autoantibody-targeted therapies in AE-IPF patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01266317.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patients with respiratory failure due to an AE-IPF showed clinical improvement after undergoing combined plasmapheresis (which would be presumed to remove offending antibodies) and anti-CD20 therapy (170).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762 · cited 2×
“[35–39] Lung histology in these acute cases is typified by the superimposed presence of diffuse alveolar damage, which is also a characteristic finding of AE-IPF.”
BackgroundMethodAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
BAFF, APRIL and their receptors: Structure, function and signaling
Bossen, C., & Schneider, P. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.006 · Cited by 521
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Evidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testing
Solomon, D. H., Kavanaugh, A. J., Schur, P. H., & American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10561 · Cited by 510 · cited 1×
“The production of antibodies with avidities for varied self-proteins is a common feature of immunological disorders, as well as being a defining criterion of “autoimmunity”.[34] Numerous distinct autoantibodies have been found in IPF cohorts,[7–17] and one or more of these self-reactive immunoglobulins are present in…”
BackgroundIntravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Gelfand, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1009433 · Cited by 495 · cited 1×
“IVIG is widely used in the management of other serious autoimmune disorders, as an adjunct with TPE and/or rituximab, to mitigate autoantibody rebound and/or provide additional immunomodulatory effects.[51,52] IVIG but was not employed in the first series of subjects, again due to our initial bias for conservatism giv…”
BackgroundPeripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381 · cited 10×
“[42] MMP7 determinations were performed in the plasma specimens to examine treatment effects on concentrations of a representative soluble non-autoantibody mediator that has been linked to IPF.”
BackgroundMethodSelf-citationFranks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
Cited by
Items 101–129 of 129
Sebastiani, M., Luppi, F., & Bendstrup, E. M. (2026) · Drugs · doi:10.1007/s40265-025-02282-x · Cited by 1
“Recently, many authors have reported possible efficacy of rituximab for the treatment of AE-ILD different from IPF, but the experience in AE-RA-ILD remains very limited [119, 120].”
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., Sgalla, G., & Richeldi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00004-5 · Cited by 1
Condoluci, C., Inchingolo, R., Mastrobattista, A., Comes, A., Golfi, N., Boccabella, C., & Richeldi, L. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10002017 · Cited by 2
Gläser, S., Glöckl, R., & Bonella, F. (2020) · Der Pneumologe · doi:10.1007/s10405-020-00313-w · Cited by 1
Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis
Kim, D. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00011-2 · Cited by 1
An Assay on Mechanisms of the Anti-Fibrotic Effects of Honey
Shoaib, A., Alqahtani, S. S., Azmi, L., Anwer, T., Khan, A., Shahrani, S. A., Ahmad, A., & Rehman, M. U. (2020) · Springer eBooks · doi:10.1007/978-981-15-7305-7_5 · Cited by 1
The Future for Idiopathic Pulmonary Fibrosis
Nathan, S. D., Brown, A. W., & King, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32794-5_9
Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Hadley, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-43341-7_30 · Cited by 2
An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis
Ohshimo, S., Costabel, U., & Shime, N. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.12.003
Pretransplant Considerations in Patients with Pulmonary Fibrosis
Carbone, R. G., Monselise, A., Wille, K. M., Bottino, G., & Puppo, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_4
Taugt bei akut exazerbierter idiopathischer Lungenfibrose der Kortisonstoß noch?
Polke, M., & Kreuter, M. (2018) · Pneumo News · doi:10.1007/s15033-018-0817-y
Future Directions for IPF Research
Craig, J. M., Aggarwal, N. R., & Kiley, J. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_20
Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis
Zhu, L.-L., Dai, H., & Wang, C. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000864
The versatile nature of MIF (macrophage migration inhibitory factor) in chronic lung diseases
Florez‐Sampedro, L. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.135375699
Is Immune Response Relevant in Interstitial Lung Disease?
Khan, M. M. (2020) · Current Immunology Reviews · doi:10.2174/1573395516999200914143054
Comorbidities and Complications of Idiopathic Pulmonary Fibrosis
Nathan, S. D., Brown, A. W., & King, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32794-5_6
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Lee, J. S., & Collard, H. R. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_17
Adaptive Immunity in Interstitial Lung Disease
Winkler, J., & Herzog, E. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00018-4
Biologics in Interstitial Lung Diseases in Rheumatological Disorders
Sharma, A., & Kumar, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-7200-2_13
Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Kumar, A., & Hadley, R. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_30
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Jain, N. K., Jain, S., Mushtaq, H. A., Khedr, A., Koritala, T., Tekin, A., Adhikari, R., Sule, A. A., Gautam, S. C., Pattan, V., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104610 · Cited by 1
Lung Transplantation in Idiopathic Pulmonary Fibrosis
Goetz, R., Jain, N. K., Anjum, H., & Kaleekal, T. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105725
Features of a telomere syndrome in patients with idiopathic pulmonary fibrosis
Hoffman, T. W. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1359
Ussavarungsi, K., Duangkham, S., Mekraksakit, P., Prasitlumkum, N., Kewcharoen, J., Childs, C., & NUGENT, K. M. (2025) · Future Rare Diseases · doi:10.1080/23995270.2025.2571386
Additional file 2 of Lung immune signatures define two groups of end-stage IPF patients
Cruz, T., Mendoza, N., Casas-Recasens, S., Noell, G. G., Hernández‐González, F., Frino-García, A., Alsina-Restoy, X., Molina, M., Rojas, M., Agustí, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620777
Additional file 1 of Lung immune signatures define two groups of end-stage IPF patients
Cruz, T., Mendoza, N., Casas-Recasens, S., Noell, G. G., Hernández‐González, F., Frino-García, A., Alsina-Restoy, X., Molina, M., Rojas, M., Agustí, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.26620774
Bellamri, N. (2019) · theses.fr (ABES) · doi:10.70675/61c916f9za0f1z4c86z8499zbe1cb4cf0b5b · Cited by 1
Tsai, K.-Y., & Gang, L. (2026) · Journal of Respiratory Biology and Translational Medicine · doi:10.70322/jrbtm.2026.10009
Metadata
- Authors
- Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-17
- Volume
- 10
- Issue
- 6
- Pages
- e0127771
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4470587
- OpenAlex
- W567581979
- Cited by
- 125
- References
- 54
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 11 · 2019: 16 · 2018: 17 · 2017: 20 · 2016: 10 · 2015: 2
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-07-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- UNC Libraries
- Funders
- University of Pittsburgh
- Medical Center, University of Pittsburgh
- National Heart, Lung, and Blood Institute (HL119960, P50HL107172, R01HL119960, HL107172)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, acute exacerbation, autoantibodies, plasma exchange, rituximab, intravenous immunoglobulin, matrix metalloproteinase-7, survival, pulmonary gas exchange
- MeSH terms
- Rituximab, Aged, Aged, 80 and over, Autoantibodies, Female, Glucocorticoids, Humans, Immunologic Factors, Lung, Male, Middle Aged, Pilot Projects, Plasma Exchange, Survival Analysis, Case-Control Studies, Immunoglobulins, Intravenous, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.